CD79A and COVID-19: For anti-RBD IgA, individuals who were infected with SARS-CoV-2 at any moment showed higher antibody levels at 4–6 months after the second dose of ChAdOx1 nCoV-19 (p = 0.0180, median—COVID-19+: 1.673; COVID-19−: 0.7415) and CoronaVac (p = 0.0136, median—COVID-19+: 1.832; COVID-19−: 0.5930) groups compared to naïve individuals (uninfected) (Figure 7A).